• N Yoshiya, S Kodama, Y Aoki, T Takahashi, S Honma, M Endo, A Tokunaga, Y Takeuchi, J Hanaoka, T Maruhashi, T Oshima, K Tanaka, and H Furue.
• Dept. of Gynecology, Niigata University School of Medicine Hospital.
• Gan To Kagaku Ryoho. 1997 Jul 1; 24 (9): 1141-7.

AbstractThe antiemetic effects on nausea and vomiting induced by anticancer drugs and safety of a 2-mg granisetron tablet were studied in cancer patients, particularly in the field of gynecology, who had been treated with anticancer drugs including cisplatin (CDDP) at 50 mg/m2 or more. The 1-mg granisetron tablet is already commercially available and used widely in clinical practice by oral administration of two tablets per dosage. In this investigation, the clinical efficacy, safety and usefulness of a 2-mg tablet, which can be taken more easily, were studied. The 2-mg granisetron tablet was judged to be "remarkably effective" or "effective" for nausea and vomiting in 22 (66.7%) of 33 patients. For safety, neither adverse experiences nor abnormal laboratory values were judged to be of clinical significance. The 2-mg granisetron tablet was considered "extremely useful" or "useful" in 22 (66.7%) of 33 patients. The above results confirmed the excellent antiemetic effect on nausea and vomiting induced by anticancer drugs including CDDP and the high degree of safety of a 2-mg granisetron tablet.

25 keywords...

hide…